Asunto(s)
Desensibilización Inmunológica/métodos , Hipersensibilidad a las Drogas/prevención & control , Factor Estimulante de Colonias de Granulocitos/administración & dosificación , Factor Estimulante de Colonias de Granulocitos/efectos adversos , Hipersensibilidad Inmediata/prevención & control , Neutropenia/tratamiento farmacológico , Adulto , Antialérgicos/uso terapéutico , Antineoplásicos/efectos adversos , Reacciones Cruzadas , Hipersensibilidad a las Drogas/diagnóstico , Hipersensibilidad a las Drogas/etiología , Hipersensibilidad a las Drogas/inmunología , Femenino , Filgrastim , Factor Estimulante de Colonias de Granulocitos/inmunología , Humanos , Hipersensibilidad Inmediata/inducido químicamente , Hipersensibilidad Inmediata/diagnóstico , Hipersensibilidad Inmediata/inmunología , Tolerancia Inmunológica , Pruebas Intradérmicas , Lenograstim , Neutropenia/inducido químicamente , Valor Predictivo de las Pruebas , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/efectos adversos , Proteínas Recombinantes/inmunología , Índice de Severidad de la Enfermedad , Resultado del TratamientoRESUMEN
No disponible
Asunto(s)
Humanos , Femenino , Adulto , Factor Estimulante de Colonias de Granulocitos/efectos adversos , Hipersensibilidad a las Drogas/terapia , Desensibilización Inmunológica , Neoplasias de la Mama/tratamiento farmacológico , Carcinoma Ductal de Mama/tratamiento farmacológicoRESUMEN
BACKGROUND: Thirty percent to ninety percent of cancer patients suffer from pain, including neuropathic pain (NP), which results in great burden for cancer patients. Thus, it was of great interest to determine NP prevalence in cancer patients in Spain, to raise awareness of the condition, and aiming to improve management of cancer NP. PATIENTS AND METHODS: A 1-month follow-up prospective epidemiological multicenter study was conducted to assess prevalence and management of NP in Spanish oncologic units. The first 10 cancer patients at each unit diagnosed with NP by the validated Douleur Neuropathique 4 questionnaire (DN4) were recruited. RESULTS: Of 8615 screened patients, 2567 (30%) suffered from pain. From these, 33% had NP according to investigators and 19% according to DN4 test. Three hundred and sixty-six patients (mean age 62.6 years; 61.2% male) were recruited. Pain decrease at 1 month was greater in patients with metastases (P<0.01) and depended on treatment (P<0.05), with 'oxycodone' showing 50.4% pain relief. CONCLUSIONS: NP prevalence in cancer pain is 33%. DN4 reports only about half the cancer NP cases diagnosed by clinicians. Pharmaceutical treatment of cancer pain, including NP, has a greater effect in patients with metastases and seems to depend on the specific treatment used.
Asunto(s)
Neoplasias/etiología , Neuralgia/epidemiología , Dimensión del Dolor , Anciano , Anciano de 80 o más Años , Analgésicos Opioides/uso terapéutico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias/epidemiología , Neuralgia/complicaciones , Neuralgia/tratamiento farmacológico , Oxicodona/uso terapéutico , España/epidemiología , Encuestas y CuestionariosRESUMEN
Patient with atypical carcinoid with pleural effusion, diffuse pulmonary involvement and subcutaneous nodule, bone metastases and mediastinal metastases as the first presentation of the carcinoid. Atypical carcinoid is defined as a higher incidence of metastases, and a worse prognosis.